



I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:

U.S. Patent and Trademark Office
Box SEQUENCE
P.O. Box 2327
Arlington, VA 22202

On 30 Oct. 2002

TOWNSEND and TOWNSEND and CREW LLP

By: Malinda C. Ogil

PATENT
Attorney Docket No.: 014740-000421US
Client Ref. No.: 0242.2 C1 D1 - emp
0035P EPI 2242.2

RECEIVED

DEC 30 2003

TECH CENTER 1600/2900

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

CHISARI, Francis V.

Application No.: 09/863,054

Filed: May 21, 2001

For: PEPTIDES FOR INDUCING
CYTOTOXIC T LYMPHOCYTE
RESPONSES TO HEPATITIS B VIRUS

Examiner: Wortman, Donna C.

Art Unit: 1648

COMMUNICATION UNDER

37 C.F.R. §§ 1.821-1.825

AND

AMENDMENT

U.S. Patent and Trademark Office
Box SEQUENCE
P.O. Box 2327
Arlington, VA 22202

Sir:

In response to the Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures, 37 C.F.R. §§ 1.821-1.825, that accompanied the Office Communication mailed October 2, 2002, Applicants submit herewith the required paper copy and computer readable copy of the Substitute Sequence Listing. Please amend the specification in adherence with 37 C.F.R. §§ 1.821-1.825 as follows.

*Please enter
New
3/15/04*